Literature DB >> 8386282

Inhibition of Epstein-Barr virus-mediated capping of CD21/CR2 by alpha interferon (IFN-alpha): immediate antiviral activity of IFN-alpha during the early phase of infection.

A X Delcayre1, M Lotz, W Lernhardt.   

Abstract

Early events of human B-lymphocyte infection by Epstein-Barr virus involve the virus binding to CD21, capping, and subsequent internalization of the virus-receptor complex. We show here that alpha interferon (IFN-alpha) inhibits the capping of Epstein-Barr virus-CD21 complexes. Synthetic peptides with the CD21 binding motif of IFN-alpha mimic IFN-alpha activity, suggesting that this effect may be mediated by IFN-alpha-CD21 interaction. Our findings demonstrate a novel and immediate mechanism of IFN-alpha action.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8386282      PMCID： PMC237619     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  14 in total

1.  VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA.

Authors:  M A EPSTEIN; B G ACHONG; Y M BARR
Journal:  Lancet       Date:  1964-03-28       Impact factor: 79.321

2.  Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2).

Authors:  G R Nemerow; R Wolfert; M E McNaughton; N R Cooper
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

3.  Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis.

Authors:  G Henle; W Henle; V Diehl
Journal:  Proc Natl Acad Sci U S A       Date:  1968-01       Impact factor: 11.205

4.  Interferon-mediated inhibition of virus penetration.

Authors:  P A Whitaker-Dowling; D K Wilcox; C C Widnell; J S Youngner
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

5.  The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA.

Authors:  N Raab-Traub; K Flynn; G Pearson; A Huang; P Levine; A Lanier; J Pagano
Journal:  Int J Cancer       Date:  1987-01-15       Impact factor: 7.396

6.  Regulation of Epstein-Barr virus infection by recombinant interferons. Selected sensitivity to interferon-gamma.

Authors:  M Lotz; C D Tsoukas; S Fong; D A Carson; J H Vaughan
Journal:  Eur J Immunol       Date:  1985-05       Impact factor: 5.532

7.  Adaptation of lymphadenopathy associated virus (LAV) to replication in EBV-transformed B lymphoblastoid cell lines.

Authors:  L Montagnier; J Gruest; S Chamaret; C Dauguet; C Axler; D Guétard; M T Nugeyre; F Barré-Sinoussi; J C Chermann; J B Brunet
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

8.  Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells.

Authors:  M Jondal; G Klein; M B Oldstone; V Bokish; E Yefenof
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

9.  Immune deficiency in the X-linked lymphoproliferative syndrome. I. Epstein-Barr virus-specific defects.

Authors:  S Harada; K Sakamoto; J K Seeley; T Lindsten; T Bechtold; J Yetz; G Rogers; G Pearson; D T Purtilo
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

10.  Replication of Epstein-Barr virus in human epithelial cells infected in vitro.

Authors:  J W Sixbey; E H Vesterinen; J G Nedrud; N Raab-Traub; L A Walton; J S Pagano
Journal:  Nature       Date:  1983 Dec 1-7       Impact factor: 49.962
View more
  8 in total

1.  Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells.

Authors:  P Monini; F Carlini; M Stürzl; P Rimessi; F Superti; M Franco; G Melucci-Vigo; A Cafaro; D Goletti; C Sgadari; S Butto'; P Leone; C Chiozzini; C Barresi; A Tinari; A Bonaccorsi; M R Capobianchi; M Giuliani; A di Carlo; M Andreoni; G Rezza; B Ensoli
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Latency type-dependent modulation of Epstein-Barr virus-encoded latent membrane protein 1 expression by type I interferons in B cells.

Authors:  Daniel Salamon; Monika Adori; Dorina Ujvari; Liang Wu; Lorand L Kis; Harsha S Madapura; Noemi Nagy; George Klein; Eva Klein
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

Review 3.  Virus receptors: implications for pathogenesis and the design of antiviral agents.

Authors:  L C Norkin
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

4.  Complement receptors regulate lipopolysaccharide-induced T-cell stimulation.

Authors:  Ziya Kaya; Theresa Tretter; Jens Schlichting; Florian Leuschner; Marina Afanasyeva; Hugo A Katus; Noel R Rose
Journal:  Immunology       Date:  2005-04       Impact factor: 7.397

5.  Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair.

Authors:  James M Kovacs; Jonathan P Hannan; Elan Z Eisenmesser; V Michael Holers
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

Review 6.  Interferon-alpha and its effects on post-transplant lymphoproliferative disorders.

Authors:  A Faro
Journal:  Springer Semin Immunopathol       Date:  1998

7.  Blocking of retroviral infection at a step prior to reverse transcription in cells transformed to constitutively express interferon beta.

Authors:  V Vieillard; E Lauret; V Rousseau; E De Maeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

8.  Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Suppresses Type I Interferon Signaling To Promote EBV Reactivation.

Authors:  XueQiao Liu; Tomohiko Sadaoka; Tammy Krogmann; Jeffrey I Cohen
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.